1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
2
|
Blum HE: Hepatocellular carcinoma: therapy
and prevention. World J Gastroenterol. 11:7391–7400.
2005.PubMed/NCBI
|
3
|
Portolani N, Coniglio A, Ghidoni S, et al:
Early and late recurrence after liver resection for hepatocellular
carcinoma: prognostic and therapeutic implications. Ann Surg.
243:229–235. 2006. View Article : Google Scholar : PubMed/NCBI
|
4
|
Poon RT and Fan ST: Resection prior to
liver transplantation for hepatocellular carcinoma: a strategy of
optimizing the role of resection and transplantation in cirrhotic
patients with preserved liver function. Liver Transpl. 10:813–815.
2004. View
Article : Google Scholar : PubMed/NCBI
|
5
|
Grepin R and Pages G: Molecular mechanisms
of resistance to tumour anti-angiogenic strategies. J Oncol.
2010:8356802010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Sanz-Cameno P, Trapero-Marugan M, Chaparro
M, Jones EA and Moreno-Otero R: Angiogenesis: from chronic liver
inflammation to hepatocellular carcinoma. J Oncol. 2010:2721702010.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Naumov GN, Folkman J and Straume O: Tumor
dormancy due to failure of angiogenesis: role of the
microenvironment. Clin Exp Metastasis. 26:51–60. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Zappala G, McDonald PG and Cole SW: Tumor
dormancy and the neuroendocrine system: an undisclosed connection?
Cancer Metastasis Rev. 32:189–200. 2013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Hisai H, Kato J, Kobune M, et al:
Increased expression of angiogenin in hepatocellular carcinoma in
correlation with tumor vascularity. Clin Cancer Res. 9:4852–4859.
2003.PubMed/NCBI
|
10
|
Pang R and Poon RT: Angiogenesis and
antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett.
242:151–167. 2006. View Article : Google Scholar : PubMed/NCBI
|
11
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
12
|
Crowther JR: ELISA. Theory and practice
Methods. Mol Biol. 42:1–218. 1995.PubMed/NCBI
|
13
|
Moserle L and Casanovas O:
Anti-angiogenesis and metastasis: a tumour and stromal cell
alliance. J Intern Med. 273:128–137. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Rak J and Klement G: Impact of oncogenes
and tumor suppressor genes on deregulation of hemostasis and
angiogenesis in cancer. Cancer Metastasis Rev. 19:93–96. 2000.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Sun HC and Tang ZY: Angiogenesis in
hepatocellular carcinoma: the retrospectives and perspectives. J
Cancer Res Clin Oncol. 130:307–319. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Schwartz M, Roayaie S and Konstadoulakis
M: Strategies for the management of hepatocellular carcinoma. Nat
Clin Pract Oncol. 4:424–432. 2007. View Article : Google Scholar : PubMed/NCBI
|
17
|
Qazi BS, Tang K and Qazi A: Recent
advances in underlying pathologies provide insight into
interleukin-8 expression-mediated inflammation and angiogenesis.
Int J Inflam. 2011:9084682011.PubMed/NCBI
|
18
|
Teicher BA: Antiangiogenic agents and
targets: A perspective. Biochem Pharmacol. 81:6–12. 2011.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Hussain F, Wang J, Ahmed R, et al: The
expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas
and pancreatic neuroendocrine tumours. Cytokine. 49:134–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Arenberg DA, Kunkel SL, Polverini PJ,
Glass M, Burdick MD and Strieter RM: Inhibition of interleukin-8
reduces tumorigenesis of human non-small cell lung cancer in SCID
mice. J Clin Invest. 97:2792–2802. 1996. View Article : Google Scholar : PubMed/NCBI
|
21
|
Moore BB, Arenberg DA, Stoy K, et al:
Distinct CXC chemokines mediate tumorigenicity of prostate cancer
cells. Am J Pathol. 154:1503–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
22
|
Ishii Y, Sakamoto T, Ito R and Yanaga K:
Anti-angiogenic therapy on hepatocellular carcinoma development and
progression. J Surg Res. 158:69–76. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Poon RT, Ng IO, Lau C, Yu WC, Fan ST and
Wong J: Correlation of serum basic fibroblast growth factor levels
with clinicopathologic features and postoperative recurrence in
hepatocellular carcinoma. Am J Surg. 182:298–304. 2001. View Article : Google Scholar
|
24
|
Yoshiji H, Kuriyama S, Yoshii J, et al:
Synergistic effect of basic fibroblast growth factor and vascular
endothelial growth factor in murine hepatocellular carcinoma.
Hepatology. 35:834–842. 2002. View Article : Google Scholar : PubMed/NCBI
|
25
|
De Luca A, Carotenuto A, Rachiglio A, et
al: The role of the EGFR signaling in tumor microenvironment. J
Cell Physiol. 214:559–567. 2008.PubMed/NCBI
|
26
|
Normanno N, Bianco C, De Luca A, Maiello
MR and Salomon DS: Target-based agents against ErbB receptors and
their ligands: a novel approach to cancer treatment. Endocr Relat
Cancer. 10:1–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
27
|
Liu S, Gong J, Morishita A, et al: Use of
protein array technology to investigate receptor tyrosine kinases
activated in hepatocellular carcinoma. Exp Ther Med. 2:399–403.
2011.PubMed/NCBI
|